Pharma's Road Map to Patient Centricity

April 16, 2019

Over the past decade, the healthcare ecosystem has slowly moved toward the “triple aim”: better healthcare experiences, improved outcomes, and a slowing of the growth of overall healthcare costs. While many pharma companies have focused on educating and engaging patients to promote shared decision-making, improved experiences and adherence, and reduced costs, many still struggle to define what patient centricity means or how to link efforts to business results.

Spotlight

Medical Brands

Imagine all simple diseases could be diagnosed, treated and prevented with self-care products… No more expensive and time-consuming doctor visits and access to the best tools and information to help users manage self-limiting diseases on their own. At Medical Brands, this is how we see the future.

OTHER WHITEPAPERS
news image

Research and Development in the Pharmaceutical Industry

whitePaper | April 1, 2021

Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Policymakers have considered policies that would lower drug prices and reduce federal drug expenditures. Such policies would probably reduce the industry’s incentive to develop new drugs.

Read More
news image

A BLOCKCHAIN TO ENSURE COUNTERFEIT FREE PHARMACEUTICAL SUPPLY CHAIN

whitePaper | February 5, 2022

Essential medicine access is one of the main objectives of healthcare systems in and pharmaceutical supply chains ensure that the right amount of medicine, with acceptable quality, will reach the customers in need

Read More
news image

2020 Prescription Drug List

whitePaper | April 7, 2020

The information in this document is designed to help you understand the prescription drug benefits offered under this plan and to compare these benefits to those offered by other plans. Information contained in this summary is designed to help you compare both the value and scope offormulary benefits.

Read More
news image

Coronavirus (COVID-19) and Its Effect on Pharmaceutical Marketing and Sales

whitePaper | March 16, 2020

With the rapid onset of coronavirus in the United States, many pharma companies are being forced to prepare for a scenario in which their reps cannot visit providers and patients are limited in their ability to visit their healthcare professionals (HCP). The CDC has gone as far as recommending the use of telemedicine and patient portals as primary channels for HCPs and patients to interact.

Read More
news image

The Next Generation of Rare Disease Drug Policy

whitePaper | April 7, 2022

The United States defines a rare disease as a condition affecting fewer than 200,000 people in the country or one in which “there is no reasonable expectation” of recovering research and development costs.1 Examples of rare diseases include genetically-linked cancers, cystic fibrosis, and debilitating pediatric conditions like Gaucher disease and spinal muscular atrophy

Read More
news image

Access to medicinal products

whitePaper | January 3, 2022

There are many factors that can prevent a patient from being able to obtain the medicine they need, ranging from selective marketing decisions by companies to products being too expensive or pharmacy stock-outs

Read More

Spotlight

Medical Brands

Imagine all simple diseases could be diagnosed, treated and prevented with self-care products… No more expensive and time-consuming doctor visits and access to the best tools and information to help users manage self-limiting diseases on their own. At Medical Brands, this is how we see the future.

Events